The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman’s disease
Abstract
Castleman's disease is a syndrome consisting of giant lymph node hyperplasia with plasma cell infiltration, fever, anemia, hypergammaglobulinemia, and an increase in the plasma level of acute phase proteins. It has been reported that clinical abnormalities disappear after the resection of the affected lymph nodes, suggesting that products of lymph nodes may cause such clinical abnormalities. Interleukin-6 (IL-6) is a cytokine inducing B-cell differentiation to immunoglobulin-producing cells and regulating biosynthesis of acute phase proteins. This report demonstrates that the germinal centers of hyperplastic lymph nodes of patients with Castleman's disease produce large quantities of IL-6 without any significant production of other cytokines. In a patient with a solitary hyperplastic lymph node, clinical improvement and decrease in serum IL-6 were observed following surgical removal of the involved lymph node. There was a correlation between serum IL-6 level, lymph node hyperplasia, hypergammaglobulinemia, increased level of acute phase proteins, and clinical abnormalities. The findings in this report indicate that the generation of IL-6 by B cells in germinal centers of hyperplastic lymph nodes of Castleman's disease may be the key element responsible for the variety of clinical symptoms in this disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Studies in the 1980s also showed that IL-6 is produced by cardiac myxoma cells (42) and Castleman’s germinal center cells (43)”
From IL-6 in inflammation, autoimmunity and cancer (2021) · cites this paper as [43]
In the citing paper
“Generally, surgical removal of hyperplastic lymph nodes results in symptomatic improvement and reduced serum IL-6 concentrations (Yoshizaki et al., 1989”
From Targeting Interleukin-6 Signaling in Clinic (2019) · cites this paper as Yoshizaki et al., 1989
Citations
Cites
Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas
Kawano, M., Hirano, T., Matsuda, T., Taga, T., Horii, Y., Iwato, K., Asaoku, H., Tang, B., Tanabe, O., Tanaka, H., et al. (1988) · Nature · doi:10.1038/332083a0 · Cited by 1,633
Self-citationHirano, T., Taga, T., Yasukawa, K., Nakajima, K., Nakano, N., Takatsuki, F., Shimizu, M., Murashima, A., Tsunasawa, S., & Sakiyama, F. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.1.228 · Cited by 351
Cited by
Sorted by citations
IL‐6 in inflammation, immunity, and disease
Tanaka, T., Narazaki, M., & Kishimoto, T. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a016295 · Cited by 5,046
“…have shown that dysregulation of IL-6 production occurs in the synovial cells of RA (Hirano et al. 1988), swollen lymph nodes of Castleman’s disease (Yoshizaki et al. 1989), myeloma cells (Kawano et al. 1988), and peripheral blood cells or involved tissues in various other autoimmune and chronic…”
BackgroundIL-6 as a keystone cytokine in health and disease
Hunter, C. A., & Jones, S. A. (2015) · Nature Immunology · doi:10.1038/ni.3153 · Cited by 2,511
Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease.
Soulier, J., Grollet, L., Oksenhendler, E., Cacoub, P., Cazals-Hatem, D., Babinet, P., d'Agay, M., Clauvel, J., Raphael, M., Degos, L., et al. (1995) · Blood · doi:10.1182/blood.v86.4.1276.bloodjournal8641276 · Cited by 2,296
Fishman, D., Faulds, G., Jeffery, R., Mohamed-Ali, V, Yudkin, J. S., Humphries, S., & Woo, P. (1998) · Journal of Clinical Investigation · doi:10.1172/jci2629 · Cited by 2,243
IL-6 in inflammation, autoimmunity and cancer
Hirano, T. (2021) · International Immunology · doi:10.1093/intimm/dxaa078 · Cited by 1,453
“Taking the above together with the fact that IL-6 is a growth factor for plasmacytoma and myeloma (28, 37) and the production of IL-6 in Castleman’s germinal center (43) suggests that IL-6 is involved in inflammation, autoimmunity and B-cell malignancies.”
BackgroundAge-Associated Increased Interleukin-6 Gene Expression, Late-Life Diseases, and Frailty
Ershler, W. B., & Keller, E. T. (2000) · Annual Review of Medicine · doi:10.1146/annurev.med.51.1.245 · Cited by 1,282
Targeting Interleukin-6 Signaling in Clinic
Kang, S., Tanaka, T., Narazaki, M., & Kishimoto, T. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.026 · Cited by 904
IL-6: From its discovery to clinical applications
Kishimoto, T. (2010) · International Immunology · doi:10.1093/intimm/dxq030 · Cited by 846
Inflammatory myofibroblastic tumours: where are we now?
Gleason, B., & Hornick, J. (2007) · Journal of Clinical Pathology · doi:10.1136/jcp.2007.049387 · Cited by 790
Nishimoto, N., Terao, K., Mima, T., Nakahara, H., Takagi, N., & Kakehi, T. (2008) · Blood · doi:10.1182/blood-2008-05-155846 · Cited by 781
Self-citationHumanized anti–interleukin-6 receptor antibody treatment of multicentric Castleman disease
Nishimoto, N., Kanakura, Y., Aozasa, K., Johkoh, T., Nakamura, M., Nakano, S., Nakano, N., Ikeda, Y., Sasaki, T., Nishioka, K., et al. (2005) · Blood · doi:10.1182/blood-2004-12-4602 · Cited by 754
Self-citationType 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases
Lucey, D. R., Clerici, M., & Shearer, G. M. (1996) · Clinical Microbiology Reviews · doi:10.1128/cmr.9.4.532 · Cited by 677
Targeting interleukin-6 in inflammatory autoimmune diseases and cancers
Yao, X., Huang, J., Zhong, H., Shen, N., Faggioni, R., Fung, M. S. C., & Yao, Y. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.09.004 · Cited by 677
“Both human and viral IL-6 can contribute to the pathogenesis of virus-infected Castleman disease (Yoshizaki et al., 1989; Aoki et al., 2001).”
BackgroundInterleukin 6: from bench to bedside
Nishimoto, N., & Kishimoto, T. (2006) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0338 · Cited by 646
Self-citationFajgenbaum, D., Uldrick, T., Bagg, A., Frank, D. M., Wu, D., Srkalović, G., Simpson, D., Liu, A. Y., Menke, D., Chandrakasan, S., et al. (2017) · Blood · doi:10.1182/blood-2016-10-746933 · Cited by 601
“The role of IL-6 as a mediator of iMCD symptomatology, histopathology, and pathogenesis has been consistently demonstrated.(13) Symptoms typically wax and wane with serum IL-6 levels, which are often elevated in iMCD, andmany patients respond to IL-6 blockade.”
BackgroundSelf-citationTranslating IL-6 biology into effective treatments
Choy, E., Benedetti, F. D., Takeuchi, T., Hashizume, M., John, M. R., & Kishimoto, T. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-020-0419-z · Cited by 680
Interleukin‐6: A Cytokine for Gerontolgists
Ershler, W. B. (1993) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1993.tb02054.x · Cited by 475
OF KAPOSI ’ S SARCOMA-ASSOCIATED HERPESVIRUS
Cotter, M., & Robertson, E. (2002) · doi:10.3390/books978-3-03842-076-7 · Cited by 477
Aoki, Y., Jaffe, E., Chang, Y., Jones, K., Teruya-Feldstein, J., Moore, P., & Tosato, G. (1999) · Blood · doi:10.1182/blood.v93.12.4034.412k38_4034_4043 · Cited by 475
Maitra, A., Yashima, K., Rathi, A., Timmons, C. F., Rogers, B. B., Shay, J. W., & Gazdar, A. F. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19990201)85:3 · Cited by 49
The Immunobiology of the Interleukin-12 Family: Room for Discovery
Wojno, E. D. T., Hunter, C. A., & Stumhofer, J. S. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.011 · Cited by 496
“In a subset of patients with Castleman’s disease, blockade of IL-6 or its receptor limits B cell proliferation and has therapeutic effects (Figure 4A) (Beck et al., 1994; Yoshizaki et al., 1989).”
The Clinical Behavior of Localized and Multicentric Castleman Disease
Herrada, J., Cabanillas, F., Rice, L., Manning, J., & Pugh, W. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-8-199804150-00010 · Cited by 428
“Type of disease, n (%) Hyaline vascular 1(25) 3(8) Plasma-cell 4 (50) 35 (92) Mixed 3 (38) Median age (range), y 35 (26-72) 64 (19-85) Constitutional symptoms, % Fatigue 100 81 Fever 31 71 Weight loss 62 58 Night sweats 62 48 Lymphadenopathy site, % Peripheral 100 100 Abdominal 62 53 Mediastinal 25 47 Splenomegaly, %…”
BackgroundB cells responses and cytokine production are regulated by their immune microenvironment
Vazquez, M. I., Catalan-Dibene, J., & Zlotnik, A. (2015) · Cytokine · doi:10.1016/j.cyto.2015.02.007 · Cited by 421
Oksenhendler, E., Boulanger, E., Galicier, L., Du, M., Dupin, N., Diss, T., Hamoudi, R., Daniel, M., Agbalika, F., Boshoff, C., et al. (2002) · Blood · doi:10.1182/blood.v99.7.2331 · Cited by 421
Lymphoproliferative disorder and imbalanced T-helper response in C/EBP beta-deficient mice
Screpanti, I., Romani, L., Musiani, P., Modesti, A., Fattori, E., Lazzaro, D., Sellitto, C., Scarpa, S., Bellavia, D., & Lattanzio, G. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb07185.x · Cited by 407
The IL-6/sIL-6R complex as a novel target for therapeutic approaches
Rose‐John, S., Waetzig, G. H., Scheller, J., Grötzinger, J., & Seegert, D. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.5.613 · Cited by 364
“This has been reported for many different diseases, for example inflammatory bowel diseases (IBD) [38-42], rheumatoid arthritis, juvenile rheumatoid arthritis and osteoarthritis [43-45], asthma and interstitial lung disease [46,47], osteoporosis [48,49], cachexia [50], sepsis [51,52], glomerulonephritis [53], multiple…”
BackgroundRhee, F. V., Voorhees, P., Dispenzieri, A., Fosså, A., Srkalović, G., Ide, M., Munshi, N., Schey, S., Streetly, M., Pierson, S., et al. (2018) · Blood · doi:10.1182/blood-2018-07-862334 · Cited by 387
Self-citationDu, M.-Q., Liu, H.-X., Diss, T., Ye, H., Hamoudi, R., Dupin, N., Meignin, V., Oksenhendler, E., Boshoff, C., & Isaacson, P. (2001) · Blood · doi:10.1182/blood.v97.7.2130 · Cited by 371
Interleukin‐6 and its receptor in cancer: Implications for Translational Therapeutics
Hong, D. S., Angelo, L. S., & Kurzrock, R. (2007) · Cancer · doi:10.1002/cncr.22999 · Cited by 370
“In patients with plasma cell-type Castleman disease, IL-6 is produced by the affected lymph nodes, and serum IL-6 levels correlate positively with clinical abnormalities.(85)”
BackgroundInterleukin (IL-6) ImmunotherapyPreprint
Tanaka, T., Narazaki, M., & Kishimoto, T. (2017) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a028456 · Cited by 419
“1988), germinal center B cells in swollen lymph nodes of Castleman disease (Yoshizaki et al. 1989), and peripheral blood cells or tissues involved in various other autoimmune and chronic inflammatory diseases and even malignant cells in cancers (Akira et al.”
BackgroundCasper, C. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05311.x · Cited by 352
“In the first study to examine the association between IL-6 production and the pathological and clinical findings of patients with CD, Yoshizaki et al (1989) described the elaboration of IL-6 from germinal centres of lymph nodes in patients with both U-PCV and MCD.”
BackgroundOksenhendler, E., Carcelain, G., Aoki, Y., Boulanger, E., Maillard, A., Clauvel, J., & Agbalika, F. (2000) · Blood · doi:10.1182/blood.v96.6.2069.h8002069_2069_2073 · Cited by 362
Interplay between interleukin-6 signaling and the vascular endothelium in cytokine storms
Kang, S., & Kishimoto, T. (2021) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00649-0 · Cited by 399
Dysregulated interleukin 6 expression produces a syndrome resembling Castleman’s disease in mice
Brandt, S. J., Bodine, D. M., Dunbar, C. E., & Nienhuis, A. W. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114749 · Cited by 248
Castleman Disease: An Update on Classification and the Spectrum of Associated Lesions
Cronin, D. M. P., & Warnke, R. (2009) · Advances in Anatomic Pathology · doi:10.1097/pap.0b013e3181a9d4d3 · Cited by 336
“The plasma cell type of CD is more commonly multicentric than unicentric, and represents 9% to 24% of localized CD.7,17,18 The localized form occurs in a similar patient population as the hyaline-vascular type18; however, the unicentric plasma cell variant is more likely to be associated with the systemic symptoms and…”
InfluentialThe varying faces of IL-6: From cardiac protection to cardiac failure
Fontes, J. A., Rose, N. R., & Čiháková, D. (2015) · Cytokine · doi:10.1016/j.cyto.2014.12.024 · Cited by 349
Fajgenbaum, D. C., van Rhee, F., & Nabel, C. S. (2014) · Blood · doi:10.1182/blood-2013-12-545087 · Cited by 336
“75 However, subsequentstudieshave not consistently demonstrated IL-6 expression by B cells and plasma cells.”
BackgroundIwakoshi, N. N., Lee, A., & Glimcher, L. H. (2003) · Immunological Reviews · doi:10.1034/j.1600-065x.2003.00057.x · Cited by 273
Selected cytokine pathways in rheumatoid arthritis
Noack, M., & Miossec, P. (2017) · Seminars in Immunopathology · doi:10.1007/s00281-017-0619-z · Cited by 313
Staskus, K., Sun, R., Miller, G., Rácz, P., Jaslowski, A., Metroka, C., Brett-Smith, H., & Haase, A. (1999) · Journal of Virology · doi:10.1128/jvi.73.5.4181-4187.1999 · Cited by 275
“Among these is a homologue of the gene for IL-6 that has clearly been associated with clinical and pathological abnormalities of MCD (4, 32) and has been speculated to play a role in KS and PEL (11).”
BackgroundIgG4‐related disease: Historical overview and pathology of hematological disorders
Sato, Y., Notohara, K., Kojima, M., Takata, K., Masaki, Y., & Yoshino, T. (2010) · Pathology international (Print) · doi:10.1111/j.1440-1827.2010.02524.x · Cited by 266
Kaposi Sarcoma-associated Herpesvirus (KSHV): Molecular Biology and Oncogenesis
Wen, K., & Damania, B. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.07.004 · Cited by 255
The Clinical Spectrum of Castleman's Disease
Dispenzieri, A., Armitage, J., Loe, M. J., Geyer, S. M., Allred, J., Camoriano, J. K., Menke, D. M., Weisenburger, D., Ristow, K. M., Dogan, A., et al. (2012) · American journal of hematology/oncology · doi:10.1002/ajh.23291 · Cited by 244
“Interleukin-6 (IL-6) is related to the pathogenesis of CD for many patients as shown by the following three observations: removal of CD mass causes an abrupt drop in IL-6 levels and resolution of symptoms [19]; treatment with IL-6 receptor antibody relieves the symptoms and signs [20,21]; overexpression of IL-6 in mic…”
BackgroundInfluentialSong, S.-N. J., Tomosugi, N., Kawabata, H., Ishikawa, T., Nishikawa, T., & Yoshizaki, K. (2010) · Blood · doi:10.1182/blood-2010-03-271791 · Cited by 228
Self-citationInterleukin-6 gene expression in Castleman's disease.
Léger-Ravet, M., Peuchmaur, M., Devergne, O., Audouin, J., Raphael, M., Damme, J. V., Galanaud, P., Diebold, J., & Emilie, D. (1991) · Blood · doi:10.1182/blood.v78.11.2923.bloodjournal78112923 · Cited by 226
Cytokines in pancreatic carcinoma
Ebrahimi, B., Tucker, S., Li, D.-H., Abbruzzese, J. L., & Kurzrock, R. (2004) · Cancer · doi:10.1002/cncr.20672 · Cited by 214
Anti-interleukin 6 receptor antibody treatment in rheumatic disease
Nishimoto, N., Kishimoto, T., & Yoshizaki, K. (2000) · Annals of the Rheumatic Diseases · doi:10.1136/ard.59.suppl_1.i21 · Cited by 222
Self-citationRhee, F. V., Oksenhendler, E., Srkalović, G., Voorhees, P., Lim, M., Dispenzieri, A., Ide, M., Parente, S. A. T., Schey, S., Streetly, M., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020003334 · Cited by 210
“Early studies correlated local production of IL-6 with the systemic manifestations seen in a minority of patients with UCD, because lymph node excision resulted in relief of symptoms along with a decrease in serum IL-6 levels.(80-82) However, levels of IL-6 and other inflammatory mediators have not been systematically…”
BackgroundSelf-citationOverproduction of proinflammatory cytokines imbalanced by their antagonists in POEMS syndrome.
Gherardi, R., Bélec, L., Soubrier, M., Malapert, D., Zuber, M., Viard, J., Intrator, L., Degos, J., & Authier, F. (1996) · Blood · doi:10.1182/blood.v87.4.1458.bloodjournal8741458 · Cited by 206
Kurzrock, R., Voorhees, P., Casper, C., Furman, R., Fayad, L., Lonial, S., Borghaei, H., Jagannath, S., Sokol, L., Usmani, S., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3349 · Cited by 202
“Overproduction of IL-6 from affected lymph nodes is responsible for systemic manifestations (12).”
BackgroundInhibition of IL-6 for the treatment of inflammatory diseases
NISHIMOTO, N. (2004) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2004.03.005 · Cited by 200
Self-citationThe full spectrum of Castleman disease: 273 patients studied over 20 years
Oksenhendler, E., Boutboul, D., Fajgenbaum, D., Mirouse, A., Fieschi, C., Malphettes, M., Vercellino, L., Meignin, V., Gérard, L., & Galicier, L. (2018) · British Journal of Haematology · doi:10.1111/bjh.15019 · Cited by 198
“In most cases of MCD, interleukin-6 (IL6), either human IL6 in iMCD or viral IL6 in HHV-8 + MCD, plays a major role in the pathophysiology of the clinical and biological symptoms of the disease (Yoshizaki et al , 1989; Brandt et al , 1990; Oksenhendler et al , 2000; Uldrick et al , 2012).”
BackgroundAngevin, E., Tabernero, J. M., Élez, E., Cohen, S. J., Bahleda, R., Laethem, J. V., Ottensmeier, C. H. H., Lopez-Martin, J. A., Clive, S., Joly, F., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2200 · Cited by 205
“every 3 weeks in MCD (19, 22), a disease in which systemic manifestations are primarily driven by IL-6 overproduction (31).”
BackgroundJudde, J., Lacoste, V., Briére, J., Kassa-Kelembho, E., Clyti, E., Couppié, P., Buchrieser, C., Tulliez, M., Morvan, J., & Gessain, A. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.9.729 · Cited by 166
Pathogenesis of Rheumatoid Arthritis: Targeting Cytokines
Zwerina, J., Redlich, K., Schett, G., & Smolen, J. (2005) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1361.116 · Cited by 161
Polizzotto, M. N., Uldrick, T. S., Wang, V., Aleman, K., Wyvill, K. M., Marshall, V., Pittaluga, S., O’Mahony, D., Whitby, D., Tosato, G., et al. (2013) · Blood · doi:10.1182/blood-2013-08-519959 · Cited by 158
IL‐6 receptor blockage inhibits the onset of autoimmune kidney disease in NZB/W F1 mice
Mihara, Takagi, Takeda, & Ohsugi (1998) · Clinical and Experimental Immunology · doi:10.1046/j.1365-2249.1998.00612.x · Cited by 155
Castleman's Disease: From Basic Mechanisms to Molecular Therapeutics
El-Osta, H. E., & Kurzrock, R. (2011) · The Oncologist · doi:10.1634/theoncologist.2010-0212 · Cited by 157
Wong, S., Bergquam, E., Swanson, R. M., Lee, F., Shiigi, S., Avery, N. A., Fanton, J., & Axthelm, M. (1999) · Journal of Experimental Medicine · doi:10.1084/jem.190.6.827 · Cited by 152
“More importantly, IL-6 dysregulation appears to be a factor in the development of MCD and multiple myeloma (61, 62).”
BackgroundGiffin, L., & Damania, B. (2014) · Advances in virus research · doi:10.1016/b978-0-12-800098-4.00002-7 · Cited by 156
“Activation of these pathways leads to expression of hIL6 (Mori et al., 2000) and VEGF (Aoki et al., 1999).”
InfluentialAnti‐interleukin‐6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases
Tanaka, T., Narazaki, M., & Kishimoto, T. (2011) · FEBS Letters · doi:10.1016/j.febslet.2011.03.023 · Cited by 148
“gical removal of the involved lymph node led to clinical improvement and reduced serum IL-6 concentration [26], suggesting that”
BackgroundFajgenbaum, D. C., Langan, R.-A., Japp, A. S., Partridge, H. L., Pierson, S. K., Singh, A., Arenas, D. J., Ruth, J. R., Nabel, C. S., Stone, K., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci126091 · Cited by 147
“Several lines of evidence implicate elevated interleukin-6 (IL-6) in the pathogenesis of some cases of iMCD (7, 8).”
AKTivation of PI3K/AKT/mTOR signaling pathway by KSHV
Bhatt, A. P., & Damania, B. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00401 · Cited by 144
“MCD is characterized by elevated serum interleukin (IL)-6 levels in the patient (Yoshizaki et al., 1989).”
BackgroundIL-6 Revisited: From Rheumatoid Arthritis to CAR T Cell Therapy and COVID-19
Kishimoto, T., & Kang, S. (2022) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101220-023458 · Cited by 140
Carbone, A., Borok, M. Z., Damania, B., Gloghini, A., Polizzotto, M. N., Jayanthan, R., Fajgenbaum, D. C., & Bower, M. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00317-7 · Cited by 214
Katsume, A., Saito, H., Yamada, Y., Yorozu, K., Ueda, O., Akamatsu, K.-I., Nishimoto, N., Kishimoto, T., Yoshizaki, K., & Ohsugi, Y. (2002) · Cytokine · doi:10.1006/cyto.2002.2012 · Cited by 134
Self-citationInterleukin-6 and rheumatic diseases.
Lipsky, P. E. (2006) · Arthritis Research & Therapy · doi:10.1186/ar1918 · Cited by 113
Yoshizaki, K., Nishimoto, N., Mihara, M., & Kishimoto, T. (1998) · Springer Seminars in Immunopathology · doi:10.1007/bf00832010 · Cited by 147
“In 1989, we demonstrated that the dysregulated production of IL-6 caused the main pathogenesis of plasma cell type of Castleman's disease [70].”
BackgroundSelf-citationSuthaus, J., Stuhlmann-Laeisz, C., Tompkins, V., Rosean, T. R., Klapper, W., Tosato, G., Janz, S., Scheller, J., & Rose-John, S. (2012) · Blood · doi:10.1182/blood-2011-09-377705 · Cited by 131
Bélec, L., Mohamed, A., Authier, F., Hallouin, M., Soe, A. M., Cotigny, S., Gaulard, P., & Gherardi, R. (1999) · Blood · doi:10.1182/blood.v93.11.3643.411k38_3643_3653 · Cited by 131
Sato, Y., Kojima, M., Takata, K., Morito, T., Mizobuchi, K., Tanaka, T., Inoue, D., Shiomi, H., Iwao, H., & Yoshino, T. (2010) · Journal of Clinical Pathology · doi:10.1136/jcp.2010.082958 · Cited by 130
“Previous reports have described that serum IgE level is elevated in MCD and idiopathic plasmacytic lymphadenopathy with polyclonal hypergammaglobulinaemia.(17) 18 On the basis of immunohistochemical findings, Cheuk et al(9) reported the diagnostic criterion for IgG4-related lymphadenopathy to be an IgG4-/IgG-positive…”
BackgroundSelective and early increase of IL‐1 inhibitors, IL‐6 and cortisol after elective surgery
Padova, F., Pozzi, C., Tondre, M., & Tritapepe, R. (1991) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.1991.tb05694.x · Cited by 128
A Review of Recent Advances Using Tocilizumab in the Treatment of Rheumatic Diseases
Rubbert-Roth, A., Furst, D., Nebesky, J., Jin, A., & Berber, E. (2018) · Rheumatology and Therapy · doi:10.1007/s40744-018-0102-x · Cited by 126
“Elevated levels of IL6 in serum, synovial fluid, and various tissues have been correlated with disease activity in patients with rheumatoid arthritis (RA) [2], juvenile idiopathic arthritis (JIA) [3, 4], Castleman’s disease [5, 6], systemic sclerosis (SSc) [7], giant cell arteritis (GCA) [8, 9], adult-onset Still’s di…”
BackgroundOcular adnexal IgG4-related lymphoplasmacytic infiltrative disorder.
Kubota, T., Moritani, S., Katayama, M., & Terasaki, H. (2010) · A M A Archives of Ophthalmology · doi:10.1001/archophthalmol.2010.45 · Cited by 125
“The elevated IL-6 serum level that leads to an overproduction of IL-6 from germinal-center B cells is implicated in the pathogenesis of multicentric Castleman disease.(17) These changes were not found in our cases.”
BackgroundHHV‐8 infection status of AIDS‐unrelated and AIDS‐associated multicentric Castleman's disease
Suda, T., Katano, H., Delsol, G., Kakiuchi, C., Nakamura, T., Shiota, M., Sata, T., Higashihara, M., & Mori, S. (2001) · Pathology International · doi:10.1046/j.1440-1827.2001.01266.x · Cited by 124
Impact of Interleukin-6 in Hematological Malignancies
Burger, R. (2013) · Transfusion Medicine and Hemotherapy · doi:10.1159/000354194 · Cited by 118
“Constitutive production of IL-6 by B cells in the germinal centers of the affected lymph nodes is associated with increased IL-6 serum levels [23].”
BackgroundThe role of the interleukin (IL)-6/IL-6 receptor axis in cancer
Taher, M. Y., Davies, D. M., & Maher, J. F. (2018) · Biochemical Society Transactions · doi:10.1042/bst20180136 · Cited by 138
Prognostic value of serum interleukin-6 in diffuse large-cell lymphoma
Preti, H. A., Cabanillas, F., Talpaz, M., Tucker, S. L., Seymour, J. F., & Kurzrock, R. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-127-3-199708010-00002 · Cited by 112
“Interleukin-6 has also been implicated in the pathogenesis of several lymphoproliferative disorders, including multiple myeloma, lymphoma, and Castleman disease (4-14), and it may be a prognostic factor for solid tumors, such as renal cell (15), epithelial ovarian (16), and prostate cancer (17).”
BackgroundBoss, I. W., Nadeau, P. E., Abbott, J. R., Yang, Y., Mergia, A., & Renne, R. (2011) · Journal of Virology · doi:10.1128/jvi.05558-11 · Cited by 123
“Previous studies have shown that miR-155 can directly target and repress reporter constructs containing portions of the C/EBP 3 UTR with the miR-155 binding site (9, 36, 57).”
BackgroundMolecular analysis of clonality in Castleman's disease.
Soulier, J., Grollet, L., Oksenhendler, E., Miclea, J., Cacoub, P., Baruchel, A., Brice, P., Clauvel, J., d'Agay, M., Raphael, M., et al. (1995) · Blood · doi:10.1182/blood.v86.3.1131.1131 · Cited by 112
Update and new approaches in the treatment of Castleman disease
Chan, K.-L., Lade, S., Prince, H., & Harrison, S. (2016) · Journal of Blood Medicine · doi:10.2147/jbm.s60514 · Cited by 109
“The pathogenic contribution of IL-6 One of the earliest links between IL-6 and CD was the demonstration that the site of excess IL-6 production in CD patients was within the germinal centers of involved lymph nodes.(22) Following lymph node resection in a patient with UCD, there was a correlation between the reduction…”
Nishi, J.-I., Arimura, K., Utsunomiya, A., Yonezawa, S., Kawakami, K., Maeno, N., Ijichi, O., Ikarimoto, N., Nakata, M., Kitajima, I., et al. (1999) · British Journal of Haematology · doi:10.1046/j.1365-2141.1999.01208.x · Cited by 109
“…IL-6 and tumour necrosis factor (TNF)-b are thought to be associated with the variety of clinical symptoms in this disease (Gherardi et al, 1994; Yoshizaki et al, 1989; Winter et al, British Journal of Haematology, 1999, 104, 482–485 482 q 1999 Blackwell Science Ltd Correspondence: Dr…”
BackgroundKojima, M., Nakamura, N., Tsukamoto, N., Otuski, Y., Shimizu, K., Itoh, H., Kobayashi, S., Kobayashi, H., Murase, T., Masawa, N., et al. (2008) · International Journal of Surgical Pathology · doi:10.1177/1066896908315812 · Cited by 104
Katsarou, A., & Pantopoulos, K. (2018) · Pharmaceuticals · doi:10.3390/ph11040127 · Cited by 115
“Castleman disease patients present with iron-refractory hypochromic microcytic anemia, which develops in response to IL-6-mediated upregulation of hepcidin [41].”
BackgroundParaneoplastic syndromes secondary to neuroendocrine tumours
Kaltsas, G., Androulakis, I. I., de Herder, W. W., & Grossman, A. B. (2010) · Endocrine Related Cancer · doi:10.1677/erc-10-0024 · Cited by 116
“A PNS presenting with fever and increased acute phase proteins has been shown to be associated with elevated IL-6 levels (Dawson & Harding 1982, Yoshizaki et al. 1989, Fukumoto et al. 1991) and related tumours to secrete IL-6 (Tabibzadeh et al. 1989, Fukumoto et al. 1991).”
BackgroundIs TAFRO syndrome a subtype of idiopathic multicentric Castleman disease?
Fujimoto, S., Sakai, T., Kawabata, H., Kurose, N., Yamada, S., Takai, K., Aoki, S., Kuroda, J., Ide, M., Setoguchi, K., et al. (2019) · American journal of hematology/oncology · doi:10.1002/ajh.25554 · Cited by 99
“IL-6 (pg/mL) 21 (10-42) (n = 76) 26 (15-40) (n = 52) 23 (13-40) (n = 12) >.”
InfluentialTocilizumab for the treatment of rheumatoid arthritis
Tanaka, T., Ogata, A., & Narazaki, M. (2010) · Expert Review of Clinical Immunology · doi:10.1586/eci.10.70 · Cited by 99
Casper, C., Chaturvedi, S., Munshi, N., Wong, R., Qi, M., Schaffer, M., Bandekar, R., Hall, B., van de Velde, H., Vermeulen, J., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0134 · Cited by 97
Recent advances in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease
Uldrick, T., Polizzotto, M., & Yarchoan, R. (2012) · Current Opinion in Oncology · doi:10.1097/cco.0b013e328355e0f3 · Cited by 97
Interleukin-6 as a Potential Therapeutic Target for Pulmonary Arterial Hypertension
Furuya, Y., Satoh, T., & Kuwana, M. (2010) · International Journal of Rheumatology · doi:10.1155/2010/720305 · Cited by 97
“The etiology of the disease appears to be heterogeneous, but dysregulated overproduction of IL-6 is believed to be responsible for the clinical abnormalities [12].”
BackgroundMethodModulation of Host Gene Expression by the K15 Protein of Kaposi's Sarcoma-Associated Herpesvirus
Brinkmann, M. M., Pietrek, M., Dittrich‐Breiholz, O., Kracht, M., & Schulz, T. F. (2006) · Journal of Virology · doi:10.1128/jvi.00648-06 · Cited by 83
“IL-6 is expressed in KSHV-associated tumors (5, 30, 31, 68, 77, 89, 131, 133) and is highly upregulated and escapes the viral host gene expression shutoff mediated by the KSHV-encoded shutoff exonuclease (ORF37) during lytic KSHV growth (42, 43).”
BackgroundRenal involvement in Castleman disease
Karoui, K. E., Vuiblet, V., Dion, D., Izzedine, H., Guitard, J., Frimat, L., Delahousse, M., Remy, P., Boffa, J., Pillebout, É., et al. (2010) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfq427 · Cited by 95
“Symptoms of CD have also been correlated with serum IL-6 levels in humans [22].”
BackgroundAnti-interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman's disease.
Matsuyama, M., Suzuki, T., Tsuboi, H., Ito, S., Mamura, M., Goto, D., Matsumoto, I., Tsutsumi, A., & Sumida, T. (2007) · Internal medicine · doi:10.2169/internalmedicine.46.6262 · Cited by 94
“Overproduction of IL-6 by germinal center B cells is implicated in the pathogenesis of MCD (2, 3).”
BackgroundThe immune system in aging: roles of cytokines, T cells and NK cells
Huang, H. W. (2005) · Frontiers in bioscience · doi:10.2741/1521 · Cited by 98
Kojima, M., Nakamura, S., Morishita, Y., Itoh, H., Yoshida, K., Ohno, Y., Oyama, T., Asano, S., Joshita, T., Mori, S., et al. (2000) · Pathology international (Print) · doi:10.1046/j.1440-1827.2000.01052.x · Cited by 92
Chadburn, A., Hyjek, E., Tam, W., Liu, Y.-F., Rengifo, T., Cesarman, E., & Knowles, D. (2008) · Histopathology · doi:10.1111/j.1365-2559.2008.03144.x · Cited by 91
Rieckmann, P., Poli, G., Kehrl, J., & Fauci, A. (1991) · Journal of Experimental Medicine · doi:10.1084/jem.173.1.1 · Cited by 91
Plasma proteomics identifies a ‘chemokine storm’ in idiopathic multicentric Castleman disease
Pierson, S. K., Stonestrom, A. J., Shilling, D., Ruth, J., Nabel, C. S., Singh, A., Ren, Y., Stone, K., Li, H., van Rhee, F., et al. (2018) · American Journal of Hematology · doi:10.1002/ajh.25123 · Cited by 90
“Several lines of evidence suggest that excess interleukin-6 (IL-6), a cytokine that promotes B cell and plasma cell growth, plays an important role in symptoms and disease progression in many iMCD patients.(11,12) Anti-IL-6 monoclonal antibodies (mAb) tocilizumab (antiIL-6 receptor) and siltuximab (anti-IL-6) have bee…”
BackgroundSugita, T., Totsuka, T., Saito, M., Yamasaki, K., Taga, T., Hirano, T., & Kishimoto, T. (1990) · Journal of Experimental Medicine · doi:10.1084/jem.171.6.2001 · Cited by 90
Ocio, E., Sanchez-Guijo, F., Díez-Campelo, M., Castilla, C., Blanco, O., Caballero, D., & Miguel, J. S. S. (2005) · American journal of hematology/oncology · doi:10.1002/ajh.20283 · Cited by 88
Metadata
- Authors
- Yoshizaki, K., Matsuda, T., Nishimoto, N., Kuritani, T., Taeho, L., Aozasa, K., Nakahata, T., Kawai, H., Tagoh, H., & Komori, T.
- Affiliations
- The University of Osaka (JP)
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 1989-09-01
- Volume
- 74
- Issue
- 4
- Pages
- 1360-1367
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W1632068222
- Cited by
- 928
- References
- 0
- Citations by year
- 2026: 11 · 2025: 27 · 2024: 23 · 2023: 15 · 2022: 29 · 2021: 20 · 2020: 32 · 2019: 18 · 2018: 33 · 2017: 37 · 2016: 21 · 2015: 38 · 2014: 35 · 2013: 34 · 2012: 25
- FWCI
- 14.01
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Blood (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Viral-associated cancers and disorders
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphadenopathy Diagnosis and Analysis
- Health Sciences › Medicine › Hematology › Autoimmune and Inflammatory Disorders Research
- Keywords
- Castleman disease, interleukin-6, germinal center, B cells, lymph node hyperplasia, hypergammaglobulinemia, acute phase proteins, plasma cell infiltration, surgical resection, cytokine production
- MeSH terms
- Adolescent, Female, Castleman Disease, Humans, Interleukins, Lymph Node Excision, Lymph Nodes, Lymphatic Diseases, Middle Aged, Interleukin-6
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
